Navigating Adjuvant Decision-Making for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer: An Expert Tumor Board Discussion

Release Date: April 20, 2022

Expiration Date: April 20, 2023

Activity Overview

This online, on-demand, virtual symposium brings together renowned experts in the management of early-stage, hormone receptor–positive/HER2-negative (HR+/HER2-) breast cancer. This multidisciplinary panel of experts engages in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents.

This educational activity is an archive of the live symposium held on April 9, 2022.

Target Audience

This educational activity is directed toward medical oncologists and surgical oncologists who are involved in the management of breast cancer. Other allied health care professionals interested in the management of breast cancer are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the utility of clinical characteristics, biomarkers, and genomic assays to assess recurrence risk in patients with early-stage, HR+/HER2- breast cancer to identify high-risk patients who may benefit from escalated adjuvant endocrine strategies
• Explain evidence from clinical trials evaluating CDK4/6 inhibitors in the adjuvant setting for patients with high-risk, early-stage, HR+/HER2- breast cancer
• Discuss the contribution of surgeons to the shared decision-making process between patients with breast cancer and their multidisciplinary care team with regard to adjuvant therapy options
• Develop strategies for preventing or managing adverse events associated with escalated adjuvant endocrine therapies for patients with high-risk, early-stage, HR+/HER2- breast cancer, including regimens that incorporate CDK4/6 inhibitors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.